Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Childhood Acute Myeloid Leukemia in Remission, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Conditions
Brief summary
This phase II trial studies the side effects and how well giving busulfan and etoposide followed by peripheral blood stem cell transplant (PBSCT) and low-dose aldesleukin works in treating patients with acute myeloid leukemia (AML). Drugs used in chemotherapy, such as busulfan and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. A PBSCT may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more cancer cells are killed. Aldesleukin may stimulate the white blood cells to kill cancer cells. Giving busulfan and etoposide together followed by PBSCT and aldesleukin may be an effective treatment for AML.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate the toxicity and overall survival of high dose Bu (busulfan)/VP-16 (etoposide) followed by post-transplant low-dose interleukin (IL)-2 (aldesleukin) in patients with AML. SECONDARY OBJECTIVES: I. To estimate the rate of relapse associated with this regimen. OUTLINE: PREPARATIVE REGIMEN: Patients receive busulfan intravenously (IV) over 2 hours or orally (PO) every 6 hours on days -7 to -4 and etoposide IV on day -3. STEM CELL INFUSION: Patients undergo autologous or syngeneic PBSC rescue on day 0. POST-TRANSPLANT ALDESLEUKIN THERAPY: Beginning 30-100 days after transplant, patients receive low-dose aldesleukin subcutaneously (SC) daily for 12 weeks. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Interventions
DRUGbusulfan
Given PO or IV
DRUGetoposide
Given IV
BIOLOGICALaldesleukin
Given SC
PROCEDUREperipheral blood stem cell transplantation
Undergo autologous or syngeneic stem cell rescue
Sponsors
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 65 Years
Healthy volunteers
No
Inclusion criteria
* The patient must have AML that falls into one of the following categories: * AML in 1st complete remission (CR) with intermediate or high risk of relapse following conventional therapy; at least, one of the following features is needed: * Patient required more than one cycle of induction to achieve first CR * White blood cell count (WBC) \> 100,000/mm\^3 at diagnosis * Any of the following cytogenetic abnormalities: inv (3), t(3:3), del (5q) or -5, 11q23, del(7q) or -7, del (20q) or -20, abnormal 12p, +11 or t8 * Any other abnormalities or combination of abnormalities which would predict intermediate or high risk of relapse * AML beyond first CR * Any patient with an identical twin donor who also meets the criteria above * Patients with AML in 1st CR should receive at least two cycles of consolidation chemotherapy prior to mobilization and transplant * Patients must have an adequate number of stem cells previously collected (i.e., \> 2 x 10\^8 total nucleated cell \[TNC\] of bone marrow \[BM\]/kg or 4 x 10\^6 \[CD\]34+ PBSC/kg, unless approved otherwise by Dr. Holmberg); prior to stem cell collection patients must be documented to be in remission and to have received two cycles of consolidation therapy after induction therapy * Pre-Study tests have been performed * Patient must sign an institutional review board (IRB) approved informed consent, conforming with federal and institutional guidelines
Exclusion criteria
* Patients with good risk AML defined by cytogenetic evaluation with these abnormalities: inversion 16 or t8;21 * Patient's life expectancy is severely limited by diseases other than AML * Patient is human immunodeficiency virus (HIV) seropositive * Patient is pregnant * Patient's creatinine \> 2.0 mg/dl * Patient's total bilirubin \> 2.0 mg/dl (unless Gilbert's disease) * Or serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase (SGPT) \>= 2.5 x upper limit of normal (ULN) not due to leukemia * Patient has a history of congestive heart failure, uncontrolled arrhythmias or left ventricular ejection fraction (LVEF) \< 50% * Patient has an unrelated human leukocyte antigen (HLA) matched donor and is eligible for a higher priority Fred Hutchinson Cancer Research Center (FHCRC) protocol (for FHCRC patients only) * Patient has an HLA matched or one antigen mismatch family donor available * Patients with a significant active infection that precludes transplant * Patients with a Karnofsky Performance Score less than 70
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival of Patients on Busulfan and Etoposide Followed by Stem Cell Rescue and Aldesleukin | From date of transplant to date of death from any cause, assessed up to 178 months | Estimated by the method of Kaplan and Meier. |
| Toxicity Associated With High-dose Busulfan and Etoposide Followed by Stem Cell Rescue | Day -7 of transplant to 100 days post transplant | Toxicity is defined as any grade 3 or grade 4 toxicity per the Bearman toxicity grading criteria following Busulfan and Etoposide high-dose chemotherapy, stem cell transplant, and the inability to recover sufficiently by day 100 to start IL-2 therapy. |
| Toxicity Associated With Aldesleukin Treatment After Stem Cell Rescue | IL-2 administration to one month after completion of IL-2 treatment | Toxicity during IL-2 therapy of any of the following per NCI Common Toxicity version 3: grade 2, 3, 4, or 5 CNS (except grade 0-3 malaise, fatigue, anxiety and depression) toxicity; grade 3, 4, or 5 non-CNS or non-hematologic toxicity; any grade 4 or 5 hematologic toxicity. |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of Patients Who Relapsed Associated With the Regimen | From date of transplant to date of death from any cause, assessed up to 178 months |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Chemo, Stem Cell Rescue, Interleukin Therapy) PREPARATIVE REGIMEN: Patients receive busulfan IV over 2 hours or PO every 6 hours on days -7 to -4 and etoposide IV on day -3.
STEM CELL INFUSION: Patients undergo autologous or syngeneic PBSC rescue on day 0.
POST-TRANSPLANT ALDESLEUKIN THERAPY: Beginning 30-100 days after transplant, patients receive low-dose aldesleukin SC daily for 12 weeks.
busulfan: Given PO or IV
etoposide: Given IV
aldesleukin: Given SC
peripheral blood stem cell transplantation: Undergo autologous or syngeneic stem cell rescue | 29 |
| Total | 29 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Screen Failed | 1 |
Baseline characteristics
| Characteristic | Treatment (Chemo, Stem Cell Rescue, Interleukin Therapy) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 28 Participants |
| Age, Continuous | 52 years |
| Region of Enrollment United States | 29 participants |
| Sex: Female, Male Female | 13 Participants |
| Sex: Female, Male Male | 16 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 29 |
| other Total, other adverse events | 29 / 29 |
| serious Total, serious adverse events | 5 / 29 |
Outcome results
Primary
Overall Survival of Patients on Busulfan and Etoposide Followed by Stem Cell Rescue and Aldesleukin
Estimated by the method of Kaplan and Meier.
Time frame: From date of transplant to date of death from any cause, assessed up to 178 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Chemo, Stem Cell Rescue, Interleukin Therapy) | Overall Survival of Patients on Busulfan and Etoposide Followed by Stem Cell Rescue and Aldesleukin | 14 Participants |
Primary
Toxicity Associated With Aldesleukin Treatment After Stem Cell Rescue
Toxicity during IL-2 therapy of any of the following per NCI Common Toxicity version 3: grade 2, 3, 4, or 5 CNS (except grade 0-3 malaise, fatigue, anxiety and depression) toxicity; grade 3, 4, or 5 non-CNS or non-hematologic toxicity; any grade 4 or 5 hematologic toxicity.
Time frame: IL-2 administration to one month after completion of IL-2 treatment
Population: 29 patients underwent autologous transplant and 21 of these patients after transplant went on to get IL-2 treatment . Toxicity for IL-2 therapy thus was only analyzed in these later 21 patients.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Chemo, Stem Cell Rescue, Interleukin Therapy) | Toxicity Associated With Aldesleukin Treatment After Stem Cell Rescue | 6 Participants |
Primary
Toxicity Associated With High-dose Busulfan and Etoposide Followed by Stem Cell Rescue
Toxicity is defined as any grade 3 or grade 4 toxicity per the Bearman toxicity grading criteria following Busulfan and Etoposide high-dose chemotherapy, stem cell transplant, and the inability to recover sufficiently by day 100 to start IL-2 therapy.
Time frame: Day -7 of transplant to 100 days post transplant
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Chemo, Stem Cell Rescue, Interleukin Therapy) | Toxicity Associated With High-dose Busulfan and Etoposide Followed by Stem Cell Rescue | 2 Participants |
Secondary
Proportion of Patients Who Relapsed Associated With the Regimen
Time frame: From date of transplant to date of death from any cause, assessed up to 178 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Chemo, Stem Cell Rescue, Interleukin Therapy) | Proportion of Patients Who Relapsed Associated With the Regimen | 16 Participants |